2-phenyl-1,3-dioxan-5-yl methanesulfonate | 26146-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 2-phenyl-1,3-dioxan-5-yl methanesulfonate
• 英文别名: (2-phenyl-1,3-dioxan-5-yl) methanesulfonate
• CAS: 26146-71-4
• 化学式: C₁₁H₁₄O₅S
• 分子量: 258.295
• InChiKey: BDNLKMOCJPCVQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-phenyl-1,3-dioxan-5-yl methanesulfonate 在 三乙基硅烷 、 二氯乙基铝 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 0.5h， 以86%的产率得到Methanesulfonic acid 2-benzyloxy-1-hydroxymethyl-ethyl ester
  参考文献：
  名称：

  A Highly Regio- and Chemoselective Reductive Cleavage of Benzylidene Acetals with EtAlCl₂-Et₃SiH

  摘要：

  在温和的条件下，使用 EtAlCl2-Et3SiH 试剂体系实现了对源自 1,2- 和 1,3- 二醇的亚苄基乙缩醛的高区域和化学选择性还原裂解，并获得了良好甚至优异的产率。在反应条件下，N-叔丁氧羰基、N-苄氧羰基和 -OTBDMS 等易变保护基团都很稳定。

  DOI：

  10.1055/s-2004-817752
• 作为产物：
  描述：

  苯甲醛 在 吡啶 、 对甲苯磺酸 作用下， 以 甲苯 、 苯 为溶剂， 反应 3.0h， 生成 2-phenyl-1,3-dioxan-5-yl methanesulfonate
  参考文献：
  名称：

  Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents

  摘要：

  On the basis of the potent antiviral activity of acyclovir and ganciclovir, selenoacyclovir (2a) and selenoganciclovir (2b) were designed based on bioisoteric rationale and synthesized via the diselenide 7 as the key intermediate. Compound 2a exhibited potent anti-HSV-1 and -2 activities while 2b exerted moderate anti-HCMV activity, indicating that these nucleosides can serve as a novel template for the development of new antiviral agents.

  DOI：

  10.1021/acs.jmedchem.5b00804

文献信息

• [EN] 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS<br/>[FR] PYRAZOLO[1,5-A] PYRAZINES SUBSTITUÉES EN 4,6 EN TANT QU'INHIBITEURS DE LA JANUS KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2016090285A1

  公开（公告）日：2016-06-09

  Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

  公式I的化合物及其立体异构体和药学上可接受的盐和溶剂化合物，在其中R1、R2、R3和R4具有规范中给定的含义，是一种或多种JAK激酶的抑制剂，并且在治疗JAK激酶相关疾病和疾病方面非常有用，如自身免疫疾病、炎症性疾病、移植器官、组织和细胞的排斥反应，以及血液学疾病和恶性肿瘤及其并发症。
• [EN] BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES<br/>[FR] COMPOSÉS DE PYRIDINE BICYCLIQUES FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASES TAM
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019113190A1

  公开（公告）日：2019-06-13

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

  本文提供了Formula (I)的化合物及其立体异构体、互变异构体和药用可接受的盐，其中环A、X1、X2、X3、R1、R2和R3如本文所定义，这些化合物是一种或多种TAM激酶的抑制剂，并且在治疗和预防可以用TAM激酶抑制剂治疗的疾病中非常有用。
• Medicinal arylethanolamine compounds
  申请人：Coe Mary Diane

  公开号：US20060205790A1

  公开（公告）日：2006-09-14

  The present invention relates to novel compounds of formula (I), and salts, solvates and physiologically acceptable derivatives thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及化合物的新型公式(I)，以及其盐，溶剂合物和生理上可接受的衍生物，其制备方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸系统疾病方面的应用。
• Pyrrolopyrazine kinase inhibitors
  申请人：Bamberg Joe Timothy

  公开号：US20090215750A1

  公开（公告）日：2009-08-27

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I的新型吡咯吡嗪衍生物，其中变量Q和R如本文所述，可以抑制JAK和SYK，并且可用于治疗自身免疫和炎症性疾病。
• PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND
  申请人：Array Biopharma Inc.

  公开号：EP3878451A1

  公开（公告）日：2021-09-15

  Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

  式 I 的化合物： 及其立体异构体和药学上可接受的盐及溶液，其中 R1、R2、R3 和 R4 具有说明书中给出的含义，是一种或多种 JAK 激酶的抑制剂，可用于治疗与 JAK 激酶相关的疾病和紊乱，如自身免疫性疾病、炎症性疾病、移植器官、组织和细胞的排斥反应，以及血液病和恶性肿瘤及其并发症。